How patients being treated for non-small cell lung cancer value treatment benefit despite side effects

Mona L Martin, Julia Correll, Andrew Walding, Anna Rydén, Mona L Martin, Julia Correll, Andrew Walding, Anna Rydén

Abstract

Purpose: To describe symptoms and side effects experienced by patients with advanced non-small cell lung cancer (NSCLC), assess how patients allocate sensations (i.e. symptoms or side effects) to either the disease or its treatment, and evaluate how patients balance side effects with treatment benefits.

Methods: Qualitative sub-studies were conducted as part of two clinical trials in patients treated for advanced NSCLC (AURA [NCT01802632]; ARCTIC [NCT02352948]).

Results: Interviews were conducted with 23 patients and 19 patients in the AURA and ARCTIC sub-studies, respectively. The most commonly experienced symptoms/side effects were respiratory (81% of patients), digestive (76%), pain and discomfort (76%), energy-related (71%), and sensory (62%). Patients identified a sensation as a treatment side effect if they had not experienced it before, if there was a temporal link between the sensation and receipt of treatment, and/or if their doctors consistently told or asked them about it in relation to side effects. Themes that emerged when patients talked about their cancer treatment and its side effects related to the serious nature of their advanced disease and their treatment expectations. Patients focused on treatment benefits, wanting a better quality of life, being hopeful, not really having a choice, and not thinking about side effects.

Conclusions: In these two qualitative sub-studies, patients with advanced NSCLC valued the benefits of their treatment regardless of side effects that they experienced. Patients weighed their options against the seriousness of their disease and expressed their willingness to tolerate their side effects in return for receiving continued treatment benefits.

Keywords: Interview studies; Non-small cell lung cancer; Qualitative; Side effects; Symptoms; Treatment benefit.

Conflict of interest statement

Anna Rydén and Andrew Walding are employees of AstraZeneca and hold shares in AstraZeneca. Julia Correll and Mona L. Martin were employed for this work by Health Research Associates, which received funds from AstraZeneca to conduct the study.

© 2021. The Author(s).

Figures

Fig. 1
Fig. 1
Key topics in interview guide. NSCLC non-small cell lung cancer

References

    1. Basch E. The missing voice of patients in drug-safety reporting. New England Journal of Medicine. 2010;362(10):865–869. doi: 10.1056/NEJMp0911494.
    1. Basch E. Toward patient-centered drug development in oncology. New England Journal of Medicine. 2013;369(5):397–400. doi: 10.1056/NEJMp1114649.
    1. Rydén A, Blackhall F, Kim HR, Pillai RN, Braam L, Martin ML, Walding A. Patient experience of symptoms and side effects when treated with osimertinib for advanced non-small-cell lung cancer: A qualitative interview substudy. Patient. 2017;10(5):593–603. doi: 10.1007/s40271-017-0229-9.
    1. European Medicines Agency. (2016). Appendix 2 to the guideline on the evaluation of anticancer medicinal products in man. The use of patient-reported outcome (PRO) measures in oncology studies. . Accessed 2 April 2020.
    1. Fromme EK, Eilers KM, Mori M, Hsieh YC, Beer TM. How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. Journal of Clinical Oncology. 2004;22(17):3485–3490. doi: 10.1200/JCO.2004.03.025.
    1. Sprangers MA, Aaronson NK. The role of health care providers and significant others in evaluating the quality of life of patients with chronic disease: A review. Journal of Clinical Epidemiology. 1992;45(7):743–760. doi: 10.1016/0895-4356(92)90052-O.
    1. Litwin MS, Lubeck DP, Henning JM, Carroll PR. Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: Results of the CaPSURE database. Journal of Urology. 1998;159(6):1988–1992. doi: 10.1016/S0022-5347(01)63222-1.
    1. Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M, Appawu M, Lasonos A, Atkinson T, Goldfarb S, Culkin A, Kris MG, Schrag D. Adverse symptom event reporting by patients vs clinicians: Relationships with clinical outcomes. Journal of the National Cancer Institute. 2009;101(23):1624–1632. doi: 10.1093/jnci/djp386.
    1. Kluetz PG, Kanapuru B, Lemery S, Johnson LL, Fiero MH, Arscott K, Barbachano Y, Basch E, Campbell M, Cappelleri JC, Cella D, Cleeland C, Coens C, Daniels S, Denlinger CS, Fairclough DL, Hillard JR, Minasian L, Mitchell SA, O’Connor D, Patel S, Rubin EH, Ryden A, Soltys K, Sridhara R, Thanarajasingam G, Velikova G, Coons SJ. Informing the tolerability of cancer treatments using patient-reported outcome measures: Summary of an FDA and Critical Path Institute workshop. Value in Health. 2018;21(6):742–747. doi: 10.1016/j.jval.2017.09.009.
    1. Jänne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, Ahn M-J, Kim S-W, Su W-C, Horn L, Haggstrom D, Felip E, Kim J-H, Frewer P, Cantarini M, Brown KH, Dickinson PA, Ghiorghiu S, Ranson M. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. New England Journal of Medicine. 2015;372(18):1689–1699. doi: 10.1056/NEJMoa1411817.
    1. Planchard D, Yokoi T, McCleod MJ, Fischer JR, Kim YC, Ballas M, Shi K, Soria JC. A phase III study of durvalumab (MEDI4736) with or without tremelimumab for previously treated patients with advanced NSCLC: Rationale and protocol design of the ARCTIC study. Clinical Lung Cancer. 2016;17(3):232–236.e1. doi: 10.1016/j.cllc.2016.03.003.
    1. Planchard D, Reinmuth N, Orlov S, Fischer JR, Sugawara S, Mandziuk S, Marquez-Medina D, Novello S, Takeda Y, Soo R, Park K. ARCTIC: Durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer. Annals of Oncology. 2020;31(5):609–618. doi: 10.1016/j.annonc.2020.02.006.
    1. Braun, V., & Clarke, V. Thematic analysis: A reflexive approach. . Accessed 5 March 2021.
    1. Braun V, Clarke V. Using thematic analysis in psychology. Qualitative Research in Psychology. 2006;3(2):77–101. doi: 10.1191/1478088706qp063oa.
    1. Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, Ring L. Content validity – Establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: Part 1 – Eliciting concepts for a new PRO instrument. Value in Health. 2011;14(8):967–977. doi: 10.1016/j.jval.2011.06.014.
    1. Saunders B, Sim J, Kingstone T, Baker S, Waterfield J, Bartlam B, Burroughs H, Jinks C. Saturation in qualitative research: Exploring its conceptualization and operationalization. Quality & Quantity. 2018;52(4):1893–1907. doi: 10.1007/s11135-017-0574-8.
    1. Cherny NI, Sullivan R, Dafni U, Kerst JM, Sobrero A, Zielinski C, de Vries EGE, Piccart MJ. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) Annals of Oncology. 2015;26(8):1547–1573. doi: 10.1093/annonc/mdv249.
    1. Niklasson A, Paty J, Ryden A. Talking about breast cancer: Which symptoms and treatment side effects are important to patients with advanced disease? Patient. 2017;10(6):719–727.
    1. Dolly SO, Kalaitzaki E, Puglisi M, Stimpson S, Hanwell J, Fandos SS, Stapleton S, Ansari T, Peckitt C, Kaye S, Lopez J, Yap TA, van der Graaf W, de Bono J, Banerji U. A study of motivations and expectations of patients seen in phase 1 oncology clinics. Cancer. 2016;122(22):3501–3508. doi: 10.1002/cncr.30235.
    1. Harrop E, Noble S, Edwards M, Sivell S, Moore B, Nelson A. Managing, making sense of and finding meaning in advanced illness: A qualitative exploration of the coping and wellbeing experiences of patients with lung cancer. Sociology of Health & Illness. 2017;39(8):1448–1464. doi: 10.1111/1467-9566.12601.
    1. Aumann I, Kreis K, Damm K, Golpon H, Welte T, Matthias Graf von der Schulenburg J. Treatment-related experiences and preferences of patients with lung cancer: A qualitative analysis. Health Expectations. 2016;19(6):1226–1236. doi: 10.1111/hex.12417.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다